Jim Cramer on Eli Lilly and Company (LLY): ‘There’s Been Some Mistakes’
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks.
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price
Eli Lilly’s (LLY) Q4 Earnings Fall Short: What’s Next for the Pharma Giant?
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far exceeding the average of 3.
Eli Lilly: BofA says buy the dip after shares slide on Q4 miss
BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.
Eli Lilly Q4 miss brings buying opportunity, says JPMorgan
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc
Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with its dominant GLP-1 drug, Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
Eli Lilly (LLY) ended the recent trading session at $797.48, demonstrating a -0.3% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day.
Eli Lilly's Q4 2024 Earnings: What to Expect
Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing medical needs.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...
24/7 Wall St. on MSN8h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Insider Monkey1d
Why Eli Lilly (LLY) Stock Is Declining Today
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...
Zacks.com on MSN5h
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...
5 Things to Know Before the Stock Market Opens
U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected ...
Yahoo Finance1d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year.
Stocktwits on MSN10h
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...